Health Condition 1: C15- Malignant neoplasm of esophagus
Conditions
Interventions
Intervention1: NIL: NIL
Sponsors
AIIMS Rishikesh
Eligibility
Inclusion criteria
Inclusion criteria: Patients with histologically confirmed diagnosis of oesophageal squamous cell carcinoma aged 18 years and above
Exclusion criteria
Exclusion criteria: 1. Oesophageal Cancer other than Squamous Cell Histology. 2. Patients in whom adequate biopsy specimen cannot be taken due to technical reasons or anatomical inaccessibility. 3. Patients with significant comorbidities which preclude full participation in the study 4. Patients who have received Radiotherapy or Chemotherapy in the past due to any other cause. 1. Oesophageal Cancer other than Squamous Cell Histology. 2. Patients in whom adequate biopsy specimen cannot be taken due to technical reasons or anatomical inaccessibility. 3. Patients with significant comorbidities which preclude full participation in the study 4. Patients who have received Radiotherapy or Chemotherapy in the past due to any other cause. 1. Oesophageal Cancer other than Squamous Cell Histology. 2. Patients in whom adequate biopsy specimen cannot be taken due to technical reasons or anatomical inaccessibility. 3. Patients with significant comorbidities which preclude full participation in the study 4. Patients who have received Radiotherapy or Chemotherapy in the past due to any other cause. 5. Recurrent Cancers or concurrent other malignancies
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Stage at Presentation: Clinical stage at presentation will be collected as per TNM AJCC 8th Edition (cTNM) and compared between the HPV positive and negative groups. Further, Tumour length, location (sub site), grade, nodal distribution and grade of dysphagia will also be compared.Timepoint: At initial Presentation | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Prevalence of HPV in oesophageal SCC assessed by PCR at initial presentation 2. Response to Chemotherapy ± radiotherapy (neoadjuvant, definitive and palliative) will be assessed by the following measures: a. Radiological Assessment: RECIST 1.1 on CECT scan b. Pathological Assessment (for patients who undergo surgery post neoadjuvant treatment): Tumour Regression Score (AJCC/CAP) Timepoint: 1. At initial presentation 2. At 6 weeks post treatment completion(Post Surgery or post Definitive or palliative CTRT) | — |
Countries
India
Contacts
Public ContactNeha Mishra
AIIMS Rishikesh
Outcome results
None listed